Exarchos, Konstantinos P.
Rovina, Nikoletta
Krommidas, George
Latsios, Dimitrios
Gogali, Athena
Kostikas, Konstantinos
Funding for this research was provided by:
Elpen Pharmaceutical Co. Inc.
Article History
Received: 20 October 2021
Accepted: 16 June 2022
First Online: 27 June 2022
Change Date: 23 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12890-022-02117-5
Declarations
:
: The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committees of the Sotiria Chest Disease Hospital and the General Hospital of Chalkida. All subjects provided written informed consent.
: Not applicable.
: K.P. Exarchos has received honoraria for presentations and consultancy fees from Novartis. N. Rovina has no conflict of interest within the scope of the submitted work and has received consultancy fees and/or funding from Chiesi, Menarini, Astra zeneca, ELPEN, CSL Behring. G. Krommidas has received honoraria for presentations and consultancy fees from AstraZeneca, Chiesi, ELPEN, GSK, Menarini, Novartis and Boehringer Ingelheim. D. Latsios reports grants and personal fees for lectures and consultancy from Chiesi, Elpen, GSK and Menarini. A. Gogali has received honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Novartis. Κ. Kostikas: I have received honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, ELPEN, GSK, Menarini, Novartis, Sanofi Genzyme and WebMD. My department has received funding and grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, ELPEN, GSK, Menarini, Novartis and NuvoAir.